deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02304458

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Melanoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Hodgkin Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma Recurrent Osteosarcoma Recurrent Rhabdomyosarcoma Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Refractory Hodgkin Lymphoma Refractory Malignant Solid Neoplasm Refractory Melanoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Osteosarcoma Refractory Rhabdomyosarcoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma
Interventions Ipilimumab Laboratory Biomarker Analysis Nivolumab Pharmacological Study
Updated 49 times since 2017 Last updated: Sep 22, 2023 Started: Mar 30, 2015 Primary completion: Sep 30, 2021 Completion: Mar 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02304458, this PHASE1/PHASE2 trial focuses on Metastatic Melanoma and Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 49 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Nov 2023 · 6 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

49 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. May 2023 — Nov 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 44 earlier versions

  1. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Nov 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Oct 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  13. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  14. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  15. Jun 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  16. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  17. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Suspended → Active Not Recruiting

  18. Feb 2020 — Apr 2020 [monthly]

    Suspended PHASE1_PHASE2

  19. Jan 2020 — Feb 2020 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  20. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  21. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  22. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  23. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  24. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  25. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  26. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  27. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  28. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  29. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  30. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  31. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  32. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  33. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  34. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  35. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  36. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  37. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  38. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  39. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  40. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  41. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  42. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  43. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  44. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aurora, United States , Bethesda, United States , Birmingham, United States , Boston, United States , Chicago, United States , Cincinnati, United States , Houston, United States , Indianapolis, United States and 15 more locations